LeMaitre Vascular (LMAT)
(Delayed Data from NSDQ)
$74.22 USD
+7.45 (11.16%)
Updated May 3, 2024 04:00 PM ET
After-Market: $74.43 +0.21 (0.28%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth B Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
LMAT 74.22 +7.45(11.16%)
Will LMAT be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for LMAT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LMAT
LeMaitre Vascular (LMAT) Q1 Earnings and Revenues Top Estimates
AtriCure's (ATRC) cryoSPHERE+ Probe to Aid in Pain Management
LMAT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why You Should Retain Medtronic (MDT) Stock for Now
Here's Why You Should Hold BD (BDX) Stock in Your Portfolio
Baxter's (BAX) New Injectables Aid Its Pharmaceutical Portfolio
Other News for LMAT
Buy Rating Affirmed: LeMaitre Vascular’s Strong Performance and Upward Financial Trajectory
LeMaitre price target raised by $10 at Barrington, here's why
Lake Street Sticks to Its Buy Rating for Lemaitre Vascular (LMAT)
Oppenheimer Reaffirms Their Buy Rating on Lemaitre Vascular (LMAT)
LeMaitre price target raised by $5 at JMP Securities, here's why